? SMALL ANIMAL IMAGING SHARED RESOURCE (SAISR) The SAISR provides critical support to OSUCCC?s preclinical imaging needs and translational therapeutic development to provide a fundamental service for monitoring live animal tumor progression and regression, metastatic spread, and response to therapeutic interventions. Services include pre-study consultation, small animal imaging, analysis and data interpretation, and education and training. Major equipment in SAISR includes a Bruker 9.4T MRI, a Vevo high frequency ultrasound, an IVIS Lumina II, a Bruker Skyscan 1276 microCT, an Xstrahl Small Animal Radiation Research Platform, and an Echo-MRI. SAISR?s Specific Aims are to: 1) provide OSUCCC investigators? access to high resolution non-invasive small animal imaging technologies that can be used to evaluate small animal cancer models and treatment therapies in vivo; 2) provide accurate qualitative image interpretation and quantitative image data analysis to al OSUCCC users; 3) identify, evaluate, and implement new and emerging technologies that address specific needs of the OSUCCC investigators; and 4) recognize and promote integration of other shared resource services that add value to investigators studies, such as the CPDISR that provides necropsy and pathology services for mice, and the MSR that provides high resolution microscopy imaging of ex vivo tissue samples. The SAISR is located within the Biomedical Research Tower, centrally located to most OSUCCC researchers. The Director of the SAISR is Dr. Kimberly Powell, who has managed the facility since 2011. The Senior Faculty Advisor is Dr. Nicholas Denko (CB), who provides overall scientific vision for the SAISR. During current grant cycle, the SAISR identified important new imaging modalities (echoMRI, the Xtrahl SAARP, and the SkyScan 1276 microCT) and worked with investigators and the OSUCCC to obtain them. During this time period, the SAISR has contributed to 41 publications (9 > 10 impact factor), 156 users, and 41 NCI including 27 R01s, 3 R21s, 4 U01s, 5 P01s, 1 P50 and 1 R03, involving members from all five programs. Given the robust OSUCCC recruitment of the OSUCCC and its research priorities, demand for services and new technologies will increase. The SAISR will expand its staff, instrumentation and services before capacity is reached. Additionally, the SAISR will add PET scanning and optoacoustic imaging. SAISR is working to: 1) develop optimized protocols for quantifying lung metastases and pancreatic tumor burden using the newly acquired microCT; 2) collaborate with the CPDISR, MSR, and TVdSR and the Genetically Engineered Mouse Models Core (a non-CCSG activity) to comprehensively characterize disease progression in mouse cancer models (i.e., lung, pancreatic, glioblastoma, and breast); and 3) expand molecular imaging capabilities. If images are digitized, they could be used for machine learning techniques. The SAISR will be a regular member of the Immune Monitoring and Discovery Platform. The annual budget is $575,505, yet the CCSG request is $61,080. Thus, the SAISR leverages extensive institutional support and seeks only 10.6% support from CCSG funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090019
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Malpeli, Giorgio; Barbi, Stefano; Greco, Corinna et al. (2018) MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma. Oncotarget 9:19961-19979
Talbert, Erin E; Lewis, Heather L; Farren, Matthew R et al. (2018) Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients. J Cachexia Sarcopenia Muscle 9:358-368
Wang, Jin-Ting; Xie, Wen-Quan; Liu, Fa-Quan et al. (2018) NADH protect against radiation enteritis by enhancing autophagy and inhibiting inflammation through PI3K/AKT pathway. Am J Transl Res 10:1713-1721
Karpurapu, Manjula; Lee, Yong Gyu; Qian, Ziqing et al. (2018) Inhibition of nuclear factor of activated T cells (NFAT) c3 activation attenuates acute lung injury and pulmonary edema in murine models of sepsis. Oncotarget 9:10606-10620
Norquist, Barbara M; Brady, Mark F; Harrell, Maria I et al. (2018) Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res 24:777-783
Zhang, Bin; Nguyen, Le Xuan Truong; Li, Ling et al. (2018) Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med 24:450-462
Tasselli, Giorgia; Filippucci, Sara; Borsella, Elisabetta et al. (2018) Yeast lipids from cardoon stalks, stranded driftwood and olive tree pruning residues as possible extra sources of oils for producing biofuels and biochemicals. Biotechnol Biofuels 11:147
Moliva, J I; Hossfeld, A P; Canan, C H et al. (2018) Exposure to human alveolar lining fluid enhances Mycobacterium bovis BCG vaccine efficacy against Mycobacterium tuberculosis infection in a CD8+ T-cell-dependent manner. Mucosal Immunol 11:968-978
Suarez-Kelly, Lorena P; Akagi, Keiko; Reeser, Julie W et al. (2018) Metaplastic breast cancer in a patient with neurofibromatosis type 1 and somatic loss of heterozygosity. Cold Spring Harb Mol Case Stud 4:
Dalton, William S; Sullivan, Daniel; Ecsedy, Jeffrey et al. (2018) Patient Enrichment for Precision-Based Cancer Clinical Trials: Using Prospective Cohort Surveillance as an Approach to Improve Clinical Trials. Clin Pharmacol Ther 104:23-26

Showing the most recent 10 out of 2602 publications